Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162591
Status:
UNKNOWN
Last Update Posted:
2005-11-22
First Post:
2005-09-10
Brief Title:
Bispectral Index as an Analgesia Monitoring in Severely Ill Patient Effect of Remifentanyl
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Assistance Publique - Hôpitaux de Paris
Study Overview
Official Title:
Bispectral Index as an Analgesia Monitoring in Severely Ill Patient Effect of Remifentanyl
Status:
UNKNOWN
Status Verified Date:
2004-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this protocol is to study the prophylactic effect of remifentanil on bispectral index variation during a nociceptive stimuli
Detailed Description:
Pain is difficult to estimate in ICU because most of the patients are sedated Bispectral index could be helpful in detecting this pain in ICU patients Remifentanil is a morphinomimetic product with short half life that could be interesting for short nociceptive stimuli as bronchoalveolar lavage
The purpose of this study is to evaluate the impact of remifentanil infusion on bispectral index BIS variations during bronchoalveolar lavage
It is a prospective double blind study versus placebo on 40 sedated and critically ill patients
The hypothesis is that BIS can study analgesia in sedated patient
The purpose of this study is to evaluate the impact of remifentanil infusion on bispectral index BIS variations during bronchoalveolar lavage
It is a prospective double blind study versus placebo on 40 sedated and critically ill patients
The hypothesis is that BIS can study analgesia in sedated patient
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None